HRP20231367T1 - Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima - Google Patents
Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima Download PDFInfo
- Publication number
- HRP20231367T1 HRP20231367T1 HRP20231367TT HRP20231367T HRP20231367T1 HR P20231367 T1 HRP20231367 T1 HR P20231367T1 HR P20231367T T HRP20231367T T HR P20231367TT HR P20231367 T HRP20231367 T HR P20231367T HR P20231367 T1 HRP20231367 T1 HR P20231367T1
- Authority
- HR
- Croatia
- Prior art keywords
- ligand
- inhibitor
- subject
- polymorphism
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664720P | 2018-04-30 | 2018-04-30 | |
| US201862681557P | 2018-06-06 | 2018-06-06 | |
| US201862784179P | 2018-12-21 | 2018-12-21 | |
| EP19796203.8A EP3774897B1 (en) | 2018-04-30 | 2019-04-26 | Methods and systems for selection and treatment of patients with inflammatory diseases |
| PCT/US2019/029402 WO2019212899A1 (en) | 2018-04-30 | 2019-04-26 | Methods and systems for selection and treatment of patients with inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231367T1 true HRP20231367T1 (hr) | 2024-02-16 |
Family
ID=68386125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231367TT HRP20231367T1 (hr) | 2018-04-30 | 2019-04-26 | Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12305236B2 (https=) |
| EP (2) | EP4296285A3 (https=) |
| JP (2) | JP2021532060A (https=) |
| KR (2) | KR20210013062A (https=) |
| CN (1) | CN112368301B (https=) |
| AU (1) | AU2019261933B2 (https=) |
| CA (1) | CA3098720A1 (https=) |
| DK (1) | DK3774897T5 (https=) |
| ES (1) | ES2962715T3 (https=) |
| FI (1) | FI3774897T3 (https=) |
| HR (1) | HRP20231367T1 (https=) |
| HU (1) | HUE063908T2 (https=) |
| LT (1) | LT3774897T (https=) |
| MA (1) | MA52251A (https=) |
| MD (1) | MD3774897T2 (https=) |
| PL (1) | PL3774897T3 (https=) |
| PT (1) | PT3774897T (https=) |
| RS (1) | RS64747B1 (https=) |
| SI (1) | SI3774897T1 (https=) |
| TW (1) | TW202003573A (https=) |
| WO (1) | WO2019212899A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014003689A (es) | 2011-09-30 | 2014-12-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos contra tl1a y sus usos. |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| ES2962715T3 (es) | 2018-04-30 | 2024-03-20 | Cedars Sinai Medical Center | Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| KR20210130168A (ko) * | 2019-02-08 | 2021-10-29 | 세다르스-신나이 메디칼 센터 | Il18r1을 표적화하는 염증성 질환의 치료를 위한 방법, 시스템 및 키트 |
| JP2022533956A (ja) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| CA3197828A1 (en) * | 2020-11-13 | 2022-05-19 | Laurens Kruidenier | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| EP4256086A4 (en) * | 2020-12-01 | 2025-01-15 | Cedars-Sinai Medical Center | METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES |
| WO2022177963A1 (en) | 2021-02-17 | 2022-08-25 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies and uses thereof |
| EP4562038A1 (en) * | 2022-07-27 | 2025-06-04 | Cephalon LLC | Anti-tl1a antibody formulations |
| CA3262839A1 (en) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| DE69334070T2 (de) | 1992-05-26 | 2007-01-04 | Immunex Corp., Thousand Oaks | Neue zytokine die cd30 binden |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| US6652854B2 (en) | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| US20060194265A1 (en) | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| US20080233119A2 (en) | 2003-08-20 | 2008-09-25 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| WO2008106451A2 (en) * | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| AU2010244640A1 (en) * | 2009-03-27 | 2011-08-11 | Merck Serono S.A. | Genetic severity markers in Multiple Sclerosis |
| US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011020906A2 (en) * | 2009-08-21 | 2011-02-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT |
| JP6124800B2 (ja) | 2011-11-30 | 2017-05-10 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬 |
| CN117264057A (zh) * | 2012-04-27 | 2023-12-22 | 诺和诺德股份有限公司 | 人cd30配体抗原结合蛋白 |
| AU2013271336B2 (en) | 2012-06-04 | 2017-11-30 | Centre For Digestive Diseases | Compositions and methods for treating Crohn's Disease and related conditions and infections |
| EP3389781B1 (en) | 2015-12-15 | 2021-08-11 | University of Miami | Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| ES2962715T3 (es) | 2018-04-30 | 2024-03-20 | Cedars Sinai Medical Center | Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias |
-
2019
- 2019-04-26 ES ES19796203T patent/ES2962715T3/es active Active
- 2019-04-26 CA CA3098720A patent/CA3098720A1/en active Pending
- 2019-04-26 RS RS20231000A patent/RS64747B1/sr unknown
- 2019-04-26 EP EP23192639.5A patent/EP4296285A3/en active Pending
- 2019-04-26 JP JP2020560463A patent/JP2021532060A/ja active Pending
- 2019-04-26 HU HUE19796203A patent/HUE063908T2/hu unknown
- 2019-04-26 FI FIEP19796203.8T patent/FI3774897T3/fi active
- 2019-04-26 SI SI201930656T patent/SI3774897T1/sl unknown
- 2019-04-26 EP EP19796203.8A patent/EP3774897B1/en active Active
- 2019-04-26 WO PCT/US2019/029402 patent/WO2019212899A1/en not_active Ceased
- 2019-04-26 AU AU2019261933A patent/AU2019261933B2/en active Active
- 2019-04-26 DK DK19796203.8T patent/DK3774897T5/da active
- 2019-04-26 MA MA052251A patent/MA52251A/fr unknown
- 2019-04-26 MD MDE20210158T patent/MD3774897T2/ro unknown
- 2019-04-26 KR KR1020207033851A patent/KR20210013062A/ko not_active Ceased
- 2019-04-26 CN CN201980044299.1A patent/CN112368301B/zh active Active
- 2019-04-26 LT LTEPPCT/US2019/029402T patent/LT3774897T/lt unknown
- 2019-04-26 US US17/051,731 patent/US12305236B2/en active Active
- 2019-04-26 PL PL19796203.8T patent/PL3774897T3/pl unknown
- 2019-04-26 KR KR1020257023772A patent/KR20250111409A/ko active Pending
- 2019-04-26 HR HRP20231367TT patent/HRP20231367T1/hr unknown
- 2019-04-26 PT PT197962038T patent/PT3774897T/pt unknown
- 2019-04-30 TW TW108115107A patent/TW202003573A/zh unknown
-
2024
- 2024-06-03 JP JP2024090213A patent/JP7832987B2/ja active Active
-
2025
- 2025-02-12 US US19/051,782 patent/US20250290143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4296285A2 (en) | 2023-12-27 |
| EP3774897A4 (en) | 2022-02-16 |
| US20210238684A1 (en) | 2021-08-05 |
| JP2024133462A (ja) | 2024-10-02 |
| CN112368301B (zh) | 2025-12-02 |
| KR20250111409A (ko) | 2025-07-22 |
| PT3774897T (pt) | 2023-11-10 |
| US12305236B2 (en) | 2025-05-20 |
| CA3098720A1 (en) | 2019-11-07 |
| CN112368301A (zh) | 2021-02-12 |
| DK3774897T3 (da) | 2023-11-06 |
| FI3774897T3 (fi) | 2023-11-03 |
| HUE063908T2 (hu) | 2024-02-28 |
| EP3774897B1 (en) | 2023-09-27 |
| MA52251A (fr) | 2021-02-17 |
| DK3774897T5 (da) | 2024-08-19 |
| AU2019261933A1 (en) | 2020-12-03 |
| EP4296285A3 (en) | 2024-02-28 |
| LT3774897T (lt) | 2023-11-10 |
| JP7832987B2 (ja) | 2026-03-18 |
| WO2019212899A1 (en) | 2019-11-07 |
| MD3774897T2 (ro) | 2024-02-29 |
| TW202003573A (zh) | 2020-01-16 |
| ES2962715T3 (es) | 2024-03-20 |
| EP3774897A1 (en) | 2021-02-17 |
| AU2019261933B2 (en) | 2025-12-18 |
| KR20210013062A (ko) | 2021-02-03 |
| RS64747B1 (sr) | 2023-11-30 |
| US20250290143A1 (en) | 2025-09-18 |
| JP2021532060A (ja) | 2021-11-25 |
| PL3774897T3 (pl) | 2024-01-29 |
| SI3774897T1 (sl) | 2024-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231367T1 (hr) | Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima | |
| JP2021532060A5 (https=) | ||
| Lindquist et al. | Cold shock proteins: from cellular mechanisms to pathophysiology and disease | |
| Glas et al. | The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population | |
| CN107109494B (zh) | Il-33介导型疾病的治疗方法和诊断方法 | |
| US20220252603A1 (en) | Method for treating cancer patients using c-met inhibitor | |
| EP2944961A1 (en) | Markers for cancer prognosis and therapy and methods of use | |
| Prager et al. | The JAK2 variant rs10758669 in Crohn’s disease: altering the intestinal barrier as one mechanism of action | |
| JP2017516458A5 (https=) | ||
| Yoshida et al. | Alu and Satα hypomethylation in Helicobacter pylori‐infected gastric mucosae | |
| WO2019153656A1 (zh) | piRNA-54265在结直肠癌的诊治和预后评价方面的应用 | |
| Chapin et al. | Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies | |
| US20170240893A1 (en) | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide | |
| KR102238912B1 (ko) | Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법 | |
| Lurje et al. | Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma | |
| Urabe et al. | Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long‐Term Effect of Infliximab against Crohn’s Disease | |
| Tavakol et al. | Interleukin-6 and tumor necrosis factor-alpha gene polymorphisms in chronic idiopathic urticaria | |
| JPWO2019212899A5 (https=) | ||
| Jung et al. | Monitoring the outcomes of systemic chemotherapy including immune checkpoint inhibitor for HER2-positive metastatic gastric cancer by liquid biopsy | |
| Pagan et al. | Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma | |
| KR102164432B1 (ko) | Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법 | |
| RU2019122099A (ru) | Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile | |
| JP2020502179A5 (https=) | ||
| Walsh et al. | Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in African-Americans | |
| Paramarta et al. | OP0156 Targeting synovial mast cells in spondyloarthritis: a proof-of-concept study with nilotinib A tyrosine kinase inhibitor |